Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.13−0.24 (-3.26%)
Close on Nov 17, 2026Market cap $382.38MP/E –Yield –
Avalo Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Avalo Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$68.29M. For fiscal 2025 it was -$51.46M. The highest annual figure on record is $12.58M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$51.46M | – |
| FY2024 | Dec 31, 2024 | -$49.06M | – |
| FY2023 | Dec 31, 2023 | -$30.68M | – |
| FY2022 | Dec 31, 2022 | -$26.75M | – |
| FY2021 | Dec 31, 2021 | -$70.89M | – |
| FY2020 | Dec 31, 2020 | -$40.54M | – |
| FY2019 | Dec 31, 2019 | -$19.13M | – |
| FY2018 | Dec 31, 2018 | -$3.13M | -124.9% |
| FY2017 | Dec 31, 2017 | $12.58M | – |
| FY2016 | Dec 31, 2016 | -$14.57M | – |
| FY2015 | Dec 31, 2015 | -$10.16M | – |
| FY2014 | Dec 31, 2014 | -$15.52M | – |
| FY2013 | Dec 31, 2013 | -$11.49M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.69M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$11.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.46M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.28M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.84M | -219.4% |
| Q2 FY2023 | Jun 30, 2023 | -$11.03M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.94M | – |
| Q3 FY2022 | Sep 30, 2022 | $5.73M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.10M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.19M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.32M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.74M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.68M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.72M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.98M | – |
| Q3 FY2018 | Sep 30, 2018 | -$538.35K | -102.8% |
| Q2 FY2018 | Jun 30, 2018 | -$333.67K | – |
| Q1 FY2018 | Mar 31, 2018 | -$280.42K | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.55M | – |
| Q3 FY2017 | Sep 30, 2017 | $19.12M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.76M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.24M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.71M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.43M | – |
See a number that looks wrong?